Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
复制标题
DOI：
10.1111/cas.14732
复制
发表时间：
2021-03
期刊：
影响因子：
5.7
通讯作者：
Zhang J
中科院分区：
文献类型：
--
作者：
Ma Y;Wang X;Qiu C;Qin J;Wang K;Sun G;Jiang D;Li J;Wang L;Shi J;Wang P;Ye H;Dai L;Jiang BH;Zhang J
The aim of this study was to develop a noninvasive serological diagnostic approach in identifying and evaluating a panel of candidate autoantibodies to tumor‐associated antigens (TAAs) based on protein microarray technology for early detection of ovarian cancer (OC). Protein microarray based on 154 proteins encoded by 138 cancer driver genes was used to screen candidate anti‐TAA autoantibodies in a discovery cohort containing 17 OC and 27 normal controls (NC). Indirect enzyme‐linked immunosorbent assay (ELISA) was used to detect the content of candidate anti‐TAA autoantibodies in sera from 140 subjects in the training cohort. Differential anti‐TAA autoantibodies were further validated in the validation cohort with 328 subjects. Subsequently, 112 sera from the patients with ovarian benign diseases with 104 OC sera and 104 NC sera together were recruited to identify the specificity of representative autoantibodies to OC among ovarian diseases. Five TAAs (GNAS, NPM1, FUBP1, p53, and KRAS) were screened out in the discovery phase, in which four of them presented higher levels in OC than controls (P < .05) in the training cohort, which was consistent with the result in the subsequent validation cohort. An optimized panel of three anti‐TAA (GNAS, p53, and NPM1) autoantibodies was identified to have relatively high sensitivity (51.2%), specificity (86.0%), and accuracy (68.6%), respectively. This panel can identify 51% of OC patients with CA125 negative. This study supports our assumption that anti‐TAA autoantibodies can be considered as potential diagnostic biomarkers for detection of OC; especially a panel of three anti‐TAA autoantibodies could be a good tool in immunodiagnosis of OC. We developed a noninvasive serological diagnostic approach of ovarian cancer (OC). Autoantibodies can be considered as potential biomarkers for the detection of OC. A panel of three anti‐TAA (GNAS, p53, and NPM1) autoantibodies was identified.
登录
查看更多内容
DOI：
10.1158/1055-9965.epi-09-0880
发表时间：
2010-03
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Anderson KS;Wong J;Vitonis A;Crum CP;Sluss PM;Labaer J;Cramer D
通讯作者：
Cramer D
基于血清蛋白质组学的分析将 PRDX2 和 PRDX3 自身抗体识别为鼻咽癌的潜在诊断生物标志物
影响因子：
3.8
作者：
Lin LH;Xu YW;Huang LS;Hong CQ;Zhai TT;Liao LD;Lin WJ;Xu LY;Zhang K;Li EM;Peng YH
通讯作者：
Peng YH
影响因子：
6.2
作者：
Bracci, Paige M.;Zhou, Mi;Young, Scott;Wiemels, Joseph
通讯作者：
Wiemels, Joseph
影响因子：
4.1
作者：
Bastepe M
通讯作者：
Bastepe M
影响因子：
--
作者：
Ebata T;Hirata H;Kawauchi K
通讯作者：
Kawauchi K